The underlying principle of the platform is to enable the identification of compounds with the most optimal safety or bioavailability profiles as early in the drug development
process as possible.
It is now apparent that one major application of toxicogenomics in drug development
is the identification and characterization of early predictive biomarkers of toxicity.
Operating as a division of Worldwide Clinical Trials over the past three years, today, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development
Australian pharmaceutical manufacturing and drug development
company, Institute of Drug Technology Australia Limited (ASX: IDT) has entered into an agreement to acquire from Mayne the business of CMAX Pty Ltd, an Adelaide-based clinical trials research unit.
Go inside the drug development
and FDA regulatory process with today's most authoritative and popular reference on the topic.
Extended Service Offering Creates Solid Drug Development
Foundation, Allowing Customers To "Get it Right the First Time"
NASDAQ: CRIS), a therapeutic drug development
company focusing on cancer, neurological and dermatological disease indications, announced today that Genentech, a collaborator, has treated the first patient in a Phase I clinical trial of a systemically administered small molecule Hedgehog antagonist for testing in advanced cancer.
Moebius has more than 16 years of strategic drug development
experience in Europe, the United States and Japan and has personally overseen the development of NCEs in epilepsy, Parkinson's disease, depression, Alzheimer's disease and vascular dementia, ADHD, spasticity, neuropathic pain, chronic pain, and addiction.
com/reports/c47910) has announced the addition of Toxicity Biomarkers: Promising Tools for Accelerated Drug Development
to their offering.
CAC), an international contract research organization specializing in oncology drug development
and medical consulting.
SSCI's CEO, Sally Byrn, who was named Vice President, Physical and Analytical Chemistry at Aptuit, stated "Together SSCI and Aptuit are in a great position to reengineer the drug development
process, bringing our customers unprecedented speed to market while helping to achieve the FDA mandate of Quality by Design.
Accium offers ultra-sensitive AMS bioanalysis, and a network of clinical and regulatory providers to reduce the time and cost of drug development